Graypoint LLC Invests $266,000 in Hologic, Inc. (NASDAQ:HOLX)

Graypoint LLC acquired a new position in shares of Hologic, Inc. (NASDAQ:HOLX) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 3,724 shares of the medical equipment provider’s stock, valued at approximately $266,000.

Several other institutional investors and hedge funds have also made changes to their positions in HOLX. Cerity Partners LLC purchased a new position in shares of Hologic during the fourth quarter worth $390,000. Seelaus Asset Management LLC raised its holdings in shares of Hologic by 16.2% during the fourth quarter. Seelaus Asset Management LLC now owns 3,485 shares of the medical equipment provider’s stock worth $249,000 after purchasing an additional 485 shares during the last quarter. Impax Asset Management Group plc raised its holdings in shares of Hologic by 32.8% during the fourth quarter. Impax Asset Management Group plc now owns 15,771 shares of the medical equipment provider’s stock worth $1,127,000 after purchasing an additional 3,895 shares during the last quarter. Sequoia Financial Advisors LLC raised its holdings in shares of Hologic by 22.0% during the fourth quarter. Sequoia Financial Advisors LLC now owns 6,598 shares of the medical equipment provider’s stock worth $471,000 after purchasing an additional 1,191 shares during the last quarter. Finally, International Assets Investment Management LLC purchased a new position in shares of Hologic during the fourth quarter worth $950,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the sale, the director now directly owns 1,572 shares in the company, valued at approximately $119,802.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the sale, the director now directly owns 1,572 shares in the company, valued at approximately $119,802.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares in the company, valued at $3,670,130.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,846 shares of company stock worth $2,473,443. 1.75% of the stock is currently owned by corporate insiders.

Hologic Price Performance

Shares of HOLX opened at $77.54 on Tuesday. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $87.88. The firm’s 50 day moving average price is $75.64 and its 200 day moving average price is $72.42. The company has a market cap of $18.20 billion, a P/E ratio of 36.75, a PEG ratio of 2.62 and a beta of 1.00. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.03. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $989.32 million. During the same period in the prior year, the firm earned $1.07 EPS. The firm’s revenue for the quarter was down 5.7% on a year-over-year basis. On average, research analysts forecast that Hologic, Inc. will post 4.02 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on HOLX. Raymond James lifted their price objective on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Evercore ISI lifted their price objective on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. StockNews.com cut shares of Hologic from a “buy” rating to a “hold” rating in a report on Friday, March 8th. Finally, William Blair reissued an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. Six investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Hologic has an average rating of “Hold” and an average target price of $87.00.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.